secwatch.observer — SEC 8-K summary
======================================

Issuer:     ESSA Pharma Inc. (—)
CIK:        0001633932
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001279569-24-000603
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ESSA Pharma Q2 net loss $9.0M; Phase 1 masofaniten combo shows 81% PSA90 in mCRPC
--------------------------------------------------------------------------------

- Net loss $9.0M (Q2 2024) vs $7.1M (Q2 2023); R&D expense $6.2M; cash $135.9M, sufficient beyond 2025.
- Phase 1 masofaniten+enzalutamide: 81% PSA90, 69% within 90 days, 63% PSA<0.2 ng/mL; median PSA progression 16.6 months.
- Phase 2 enrollment completion expected Q1 2025; preliminary data mid-2025; ~25 sites active, 15 European sites by Q3 2024.
- Additional arms enrolling: masofaniten+abiraterone/prednisone and +apalutamide; Phase 1b monotherapy results H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1633932/000127956924000603/0001279569-24-000603-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1633932/000127956924000603/form8k.htm
  HTML page:      https://secwatch.observer/filing/0001279569-24-000603

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer